临床病原菌磷霉素耐药机制研究进展

doi:10.3969/j.issn.1673-8640.2022.010.017

摘要/Abstract

摘要：

近年来，多重耐药和泛耐药病原菌不断产生，新的抗菌药物研发速度已无法满足临床治疗需求。磷霉素和多黏菌素等抗菌药物被重新用于临床抗感染治疗。磷霉素对革兰阳性菌和革兰阴性菌有独特的作用机制，不易产生交叉耐药，仍有较好的临床应用价值。文章对磷霉素的耐药机制，如murA发生突变引起的磷霉素耐药、膜转运体的结构基因突变、质粒介导的磷霉素修饰酶，以及异质性耐药等耐药机制进行综述。

关键词: 磷霉素, 耐药机制, murA突变, 膜转运体, 磷霉素修饰酶, 异质性耐药

Abstract:

With the spread of multidrug-resistant or extensively drug resistant pathogens and the lack of new antibiotics，many old antibiotics，such as fosfomycin and polymyxin，are reused for anti-infection treatment in clinic. Fosfomycin has a unique mechanism against Gram-positive and Gram-negative bacteria. Cross-resistance is not common. This review mainly focuses on drug resistance mechanism to fosfomycin，such as drug resistance caused by murA mutations，mutations in the chromosomal genes encoding fosfomycin transporters，acquisition of plasmid-encoded genes encoding fosfomycin-modifying enzymes and hetero-resistance to fosfomycin.

Key words: Fosfomycin, Drug resistance mechanism, murA mutation, Membrane transporter, Fosfomycin-modifying enzyme, Hetero-resistance

中图分类号:

R446.5

王立新, 苏云福, 王毅. 临床病原菌磷霉素耐药机制研究进展[J]. 检验医学, 2022, 37(10): 993-997.

WANG Lixin, SU Yunfu, WANG Yi. Research progress on the drug resistance mechanism of clinical pathogens to fosfomycin[J]. Laboratory Medicine, 2022, 37(10): 993-997.

参考文献 33

[1]	MÚÑEZ RUBIO E, RAMOS MARTÍNEZ A, FERNÁNDEZ CRUZ A. Fosfomycin in antimicrobial stewardship programs[J]. Rev Esp Quimioter, 2019, 32(Suppl 1):62-66.
[2]	LEE Y C, CHEN P Y, WANG J T, et al. Prevalence of fosfomycin resistance and gene mutations in clinical isolates of methicillin-resistant Staphylococcus aureus[J]. Antimicrob Resist Infect Control, 2020, 9(1):135. DOI URL
[3]	FALAGAS M E, ATHANASAKI F, VOULGARIS G L, et a1. Resistance to fosfomycin:mechanisms,frequency and clinical consequences[J]. Int J Antimicrob Agents, 2019, 53(1):22-28. DOI URL
[4]	ZHANG X, BI W, CHEN L, et al. Molecular mechanisms and epidemiology of fosfomycin resistance in Enterococci isolated from patients at a teaching hospital in China,2013-2016[J]. J Glob Antimicrob Resist, 2020, 20:191-196. DOI URL
[5]	SEOK H, CHOI J Y, WI Y M, et al. Fosfomycin resistance in Escherichia coli isolates from South Korea and in vitro activity of fosfomycin alone and in combination with other antibiotics[J]. Antibiotics(Basel), 2020, 9(3):112.
[6]	LIU P, CHEN S, WU Z Y, et al. Mechanisms of fosfomycin resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae[J]. J Glob Antimicrob Resist, 2020, 22:238-243. DOI URL
[7]	DÍEZ-AGUILAR M, CANTÓN R. New microbiological aspects of fosfomycin[J]. Rev Esp Quimioter, 2019, 32(Suppl 1):8-18.
[8]	XU W, CHEN T, WANG H, et al. Molecular mechanisms and epidemiology of fosfomycin resistance in Staphylococcus aureus isolated from patients at a teaching hospital in China[J]. Front Microbiol, 2020, 11:1290. DOI URL
[9]	SORLOZANO-PUERTO A, LOPEZ-MACHADO I, ALBERTUZ-CRESPO M, et al. Characterization of fosfomycin and nitrofurantoin resistance mechanisms in Escherichia coli isolated in clinical urine samples[J]. Antibiotics(Basel), 2020, 9(9):534.
[10]	SINGKHAM-IN U, MUHUMMUDAREE N, CHATSUWAN T. FosA3 overexpression with transporter mutations mediates high-level of fosfomycin resistance and silence of fosA3 in fosfomycin-susceptible Klebsiella pneumoniae producing carbapenemase clinical isolates[J]. PLoS One, 2020, 15(8):e0237474.
[11]	CATTOIR V, POURBAIX A, MAGNAN M, et al. Novel chromosomal mutations responsible for fosfomycin resistance in Escherichia coli[J]. Front Microbiol, 2020, 11:575031. DOI URL
[12]	HUANG Y, LIN Q, ZHOU Q, et al. Identification of fosA10,a novel plasmid-mediated fosfomycin resistance gene of Klebsiella pneumonia origin,in Escherichia coli[J]. Infect Drug Resist, 2020, 13:1273-1279. DOI URL
[13]	ZURFLUH K, TREIER A, SCHMITT K, et al. Mobile fosfomycin resistance genes in Enterobacteriaceae-an increasing threat[J]. Microbiologyopen, 2020, 9(12):e1135.
[14]	YANG T Y, LU P L, TSENG S P. Update on fosfomycin-modified genes in Enterobacteriaceae[J]. J Microbiol Immunol Infect, 2019, 52(1):9-21. DOI URL
[15]	WANG H, MIN C, LI J, et al. Characterization of fosfomycin resistance and molecular epidemiology among carbapenem-resistant Klebsiella pneumoniae strains from two tertiary hospitals in China[J]. BMC Microbiol, 2021, 21(1):109. DOI URL
[16]	HUANG L, CAO M, HU Y, et al. Prevalence and mechanisms of fosfomycin resistance among KPC-producing Klebsiella pneumoniae clinical isolates in China[J]. Int J Antimicrob Agents, 2021, 57(1):106226. DOI URL
[17]	MOWLABOCCUS S, DALEY D, PANG S, et al. Identification and characterisation of fosfomycin resistance in Escherichia coli urinary tract infection isolates from Australia[J]. Int J Antimicrob Agents, 2020, 56(4):106121. DOI URL
[18]	LORAS C, GONZÁLEZ-PRIETO A, PÉREZ-VÁZQUEZ M, et al. Prevalence, detection and characterisation of fosfomycin-resistant Escherichia coli strains carrying fosA genes in community of Madrid,Spain[J]. J Glob Antimicrob Resist, 2021, 25:137-141. DOI URL
[19]	POIREL L, VUILLEMIN X, KIEFFER N, et al. Identification of fosA8,a plasmid-encoded fosfomycin resistance determinant from Escherichia coli,and its origin in Leclercia adecarboxylata[J]. Antimicrob Agents Chemother, 2019, 63(11):e01403-e01419.
[20]	TEN DOESSCHATE T, ABBOTT I J, WILLEMS R J L, et al. In vivo acquisition of fosfomycin resistance in Escherichia coli by fosA transmission from commensal flora[J]. J Antimicrob Chemother, 2019, 74(12):3630-3632. DOI URL
[21]	ITO R, MUSTAPHA M M, TOMICH A D, et al. Widespread fosfomycin resistance in Gram-negative bacteria attributable to the chromosomal fosA gene[J]. mBio, 2017, 8(4):e00749-17.
[22]	KIEFFER N, POIREL L, MUELLER L, et al. IS Ecp1-mediated transposition leads to fosfomycin and broad-spectrum cephalosporin resistance in Klebsiella pneumoniae[J]. Antimicrob Agents Chemother, 2020, 64(5):e00150-20.
[23]	CHEN C, XU X, QU T, et al. Prevalence of the fosfomycin-resistance determinant,fosB3,in Enterococcus faecium clinical isolates from China[J]. J Med Microbiol, 2014, 63(Pt 11):1484-1489. DOI URL
[24]	MOTA M I, VÁZQUEZ S, CORNEJO C, et al. Does shiga toxin-producing Escherichia coli and Listeria monocytogenes contribute significantly to the burden of antimicrobial resistance in Uruguay?[J]. Front Vet Sci, 2020, 7:583930. DOI URL
[25]	LEITE G C, PERDIGÃO-NETO L V, RUEDAS MARTINS R C, et al. Genetic factors involved in fosfomycin resistance of multidrug-resistant Acinetobacter baumannii[J]. Infect Genet Evol, 2021, 93:104943. DOI URL
[26]	TRAVIS S, SHAY M R, MANABE S, et al. Characterization of the genomically encoded fosfomycin resistance enzyme from Mycobacterium abscessus[J]. Medchemcomm, 2019, 10(11):1948-1957. DOI URL
[27]	KHABTHANI S, HAMEL M, BARON S A, et al. FosM,a new family of fosfomycin resistance genes identified in bacterial species isolated from human microbiota[J]. Antimicrob Agents Chemother, 2021, 65(2):e01712-e01720.
[28]	KIEFFER N, POIREL L, DESCOMBES M C, et al. Characterization of fosL1,a plasmid-encoded fosfomycin resistance protein identified in Escherichia coli[J]. Antimicrob Agents Chemother, 2020, 64(4):e02042-19.
[29]	KOBAYASHI S, KUZUYAMA T, SETO H. Characterization of the fomA and fomB gene products from Streptomyces wedmorensis,which confer fosfomycin resistance on Escherichia coli[J]. Antimicrob Agents Chemother, 2000, 44(3):647-650. DOI URL
[30]	CASTAÑEDA-GARCÍA A, BLÁZQUEZ J, RODRÍGUEZ-ROJAS A. Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance[J]. Antibiotics(Basel), 2013, 2(2):217-236.
[31]	ANDERSSON D I, NICOLOFF H, HJORT K. Mechanisms and clinical relevance of bacterial heteroresistance[J]. Nat Rev Microbiol, 2019, 17(8):479-496. DOI PMID
[32]	ENGEL H, GUTIÉRREZ-FERNÁNDEZ J, FLÜCKIGER C, et al. Heteroresistance to fosfomycin is predominant in Streptococcus pneumoniae and depends on the murA1 gene[J]. Antimicrob Agents Chemother, 2013, 57(6):2801-2808. DOI URL
[33]	PORTILLO-CALDERÓN I, ORTIZ-PADILLA M, RODRÍGUEZ-MARTÍNEZ J M, et al. Contribution of hypermutation to fosfomycin heteroresistance in Escherichia coli[J]. J Antimicrob Chemother, 2020, 75(8):2066-2075.